132 related articles for article (PubMed ID: 19195334)
1. The maturation inhibitor bevirimat (PA-457) can be active in patients carrying HIV type-1 non-B subtypes and recombinants.
Yebra G; Holguín A
Antivir Ther; 2008; 13(8):1083-5. PubMed ID: 19195334
[TBL] [Abstract][Full Text] [Related]
2. High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor.
Seclén E; González Mdel M; Corral A; de Mendoza C; Soriano V; Poveda E
AIDS; 2010 Jan; 24(3):467-9. PubMed ID: 19996935
[TBL] [Abstract][Full Text] [Related]
3. Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
Malet I; Wirden M; Derache A; Simon A; Katlama C; Calvez V; Marcelin AG
AIDS; 2007 Apr; 21(7):871-3. PubMed ID: 17415044
[TBL] [Abstract][Full Text] [Related]
4. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
[TBL] [Abstract][Full Text] [Related]
5. Determinants of activity of the HIV-1 maturation inhibitor PA-457.
Li F; Zoumplis D; Matallana C; Kilgore NR; Reddick M; Yunus AS; Adamson CS; Salzwedel K; Martin DE; Allaway GP; Freed EO; Wild CT
Virology; 2006 Dec 5-20; 356(1-2):217-24. PubMed ID: 16930665
[TBL] [Abstract][Full Text] [Related]
6. Resistance to Second-Generation HIV-1 Maturation Inhibitors.
Urano E; Timilsina U; Kaplan JA; Ablan S; Ghimire D; Pham P; Kuruppu N; Mandt R; Durell SR; Nitz TJ; Martin DE; Wild CT; Gaur R; Freed EO
J Virol; 2019 Mar; 93(6):. PubMed ID: 30567982
[TBL] [Abstract][Full Text] [Related]
7. [Prediction of the efficacy of bevirimat used for the treatment of HIV infection in Russia].
Kazennova EV; Vasil'ev AV; Bobkova MR
Vopr Virusol; 2010; 55(3):37-41. PubMed ID: 20608080
[TBL] [Abstract][Full Text] [Related]
8. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
9. In vitro resistance to the human immunodeficiency virus type 1 maturation inhibitor PA-457 (Bevirimat).
Adamson CS; Ablan SD; Boeras I; Goila-Gaur R; Soheilian F; Nagashima K; Li F; Salzwedel K; Sakalian M; Wild CT; Freed EO
J Virol; 2006 Nov; 80(22):10957-71. PubMed ID: 16956950
[TBL] [Abstract][Full Text] [Related]
10. Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure.
Holguín A; Suñe C; Hamy F; Soriano V; Klimkait T
J Clin Virol; 2006 Aug; 36(4):264-71. PubMed ID: 16765636
[TBL] [Abstract][Full Text] [Related]
11. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.
Yaotsè DA; Nicole V; Roch NF; Mireille PD; Eric D; Martine P
Infect Genet Evol; 2009 Jul; 9(4):646-52. PubMed ID: 19460333
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients.
Verheyen J; Knops E; Kupfer B; Hamouda O; Somogyi S; Schuldenzucker U; Hoffmann D; Kaiser R; Pfister H; Kücherer C
J Infect; 2009 Jan; 58(1):61-7. PubMed ID: 19110315
[TBL] [Abstract][Full Text] [Related]
13. Evolution and predictors of HIV type-1 drug resistance in patients failing combination antiretroviral therapy in Italy.
Di Giambenedetto S; Zazzi M; Corsi P; Gonnelli A; Di Pietro M; Giacometti A; Almi P; Trezzi M; Boeri E; Gianotti N; Menzo S; Del Gobbo R; Francisci D; Nerli A; Galli L; De Luca A;
Antivir Ther; 2009; 14(3):359-69. PubMed ID: 19474470
[TBL] [Abstract][Full Text] [Related]
14. High prevalence of bevirimat resistance mutations in protease inhibitor-resistant HIV isolates.
Verheyen J; Verhofstede C; Knops E; Vandekerckhove L; Fun A; Brunen D; Dauwe K; Wensing AM; Pfister H; Kaiser R; Nijhuis M
AIDS; 2010 Mar; 24(5):669-73. PubMed ID: 19926962
[TBL] [Abstract][Full Text] [Related]
15. Bevirimat: a novel maturation inhibitor for the treatment of HIV-1 infection.
Martin DE; Salzwedel K; Allaway GP
Antivir Chem Chemother; 2008; 19(3):107-13. PubMed ID: 19024627
[TBL] [Abstract][Full Text] [Related]
16. Discordant genotypic interpretation and phenotypic role of protease mutations in HIV-1 subtypes B and G.
Santos AF; Abecasis AB; Vandamme AM; Camacho RJ; Soares MA
J Antimicrob Chemother; 2009 Mar; 63(3):593-9. PubMed ID: 19136678
[TBL] [Abstract][Full Text] [Related]
17. The sequence of the CA-SP1 junction accounts for the differential sensitivity of HIV-1 and SIV to the small molecule maturation inhibitor 3-O-{3',3'-dimethylsuccinyl}-betulinic acid.
Zhou J; Chen CH; Aiken C
Retrovirology; 2004 Jun; 1():15. PubMed ID: 15225375
[TBL] [Abstract][Full Text] [Related]
18. Alkyl Amine Bevirimat Derivatives Are Potent and Broadly Active HIV-1 Maturation Inhibitors.
Urano E; Ablan SD; Mandt R; Pauly GT; Sigano DM; Schneider JP; Martin DE; Nitz TJ; Wild CT; Freed EO
Antimicrob Agents Chemother; 2016 Jan; 60(1):190-7. PubMed ID: 26482309
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
Cardoso LP; Queiroz BB; Stefani MM
J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
[TBL] [Abstract][Full Text] [Related]
20. A single G10T polymorphism in HIV-1 subtype C Gag-SP1 regulates sensitivity to maturation inhibitors.
Ghimire D; Kc Y; Timilsina U; Goel K; Nitz TJ; Wild CT; Gaur R
Retrovirology; 2021 Apr; 18(1):9. PubMed ID: 33836787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
